U.S. researchers made the super-aspirin efficacy Strong is about 25 times

U.S. researchers two aspirin derivatives mixed together to make a "super aspirin. The experimental results show that this new type of aspirin can inhibit the growth of more than ten kinds of cancer, and non-destructive mice normal cells. The researchers said the "super aspirin developed into drugs people are still a few years.

Derivatives of a mixture of
City College of New York researchers published this month, "American Chemical Society Drug Chemical Letters papers wrote that this new type of aspirin can inhibit colon cancer, pancreatic cancer, lung cancer, prostate cancer, breast cancer, leukemia and other 11 kinds of malignant cell growth, and not prejudicial to the normal cells.

This "super" aspirin called nitric oxide hydrogen sulfide (NOSH) aspirin, a mixture of previously developed two aspirin derivatives, a derivative of the release of nitric oxide, help protect the gastric mucosa, another release of hydrogen sulfide to enhance the ability of aspirin cancer.

The researchers found that mixing up of two kinds of derivatives more secure than any one alone; on anti-cancer effect in terms of a mixture of aspirin stronger than nitric oxide 1.5 times, 80 times stronger than the hydrogen sulfide aspirin.



This means that this mixture to develop drugs that, just fewer doses will be able to play a sufficient role to reduce the potential side effects.

The pharmacodynamic strong about 25 times
The researchers found that the effectiveness of nitric oxide hydrogen sulfide of aspirin on cancer cells in a petri dish, 24 hours after 000 times stronger than ordinary aspirin 72 hours after strong about 25 times.

The second experiment, the researchers gave mice carrying the human colon cancer and oral nitric oxide hydrogen sulfide aspirin, the results of cancer cells self-destructive, tumor shrinkage of 85%, effectively inhibit cancer cell proliferation, significantly delayed tumor growth , and toxic side effects on mice.

Organized by the American Association for the Advancement of Science EurekAlert website quoted study leader the non Huo Silao Cash, associate professor at City College of New York as saying: "the main component of this new mixture is very effective, but also for the (normal) cell toxicity is minimal."

Market still need to wait
Cash non-said: "If we see in animals (effect) to transfer the person body, it can be used in conjunction with other drugs to shrink the tumor before chemotherapy or surgical resection.

Cash non-wrote in a research report, the next step will be to conduct toxicity testing and clinical trials, in order to develop drugs for human "super aspirin market still needs a few years.

Previous data show that long-term use of aspirin, the risk of colon cancer than non-patients and an average reduction of 50%, but may have serious side effects such as bleeding, ulcers, kidney failure.